Cargando…

Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network

INTRODUCTION: Carfilzomib, a potent, irreversible, selective proteasome inhibitor has demonstrated consistent results in relapsed/refractory multiple myeloma (RRMM) combined with lenalidomide and dexamethasone (KRd). No prospective studies are yet available that analyzed the efficacy of the KRd comb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Antonioli, Elisabetta, Pilerci, Sofia, Attucci, Irene, Buda, Gabriele, Gozzetti, Alessandro, Candi, Veronica, Simonetti, Federico, Giudice, Maria Livia Del, Ciofini, Sara, Staderini, Michela, Grammatico, Sara, Buzzichelli, Alessandra, Messeri, Maria, Bocchia, Monica, Galimberti, Sara, Vannucchi, Alessandro M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166989/ https://www.ncbi.nlm.nih.gov/pubmed/37182182 http://dx.doi.org/10.3389/fonc.2023.1162990

Ejemplares similares

P48 CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE REAL-LIFE EXPERIENCE OF THE REGIONAL TUSCAN MYELOMA NETWORK (RTM)
por: Attucci, I., et al.
Publicado: (2023)

Daratumumab in AL Amyloidosis: A Real-Life Experience of the “RTM” (Regional Tuscan Myeloma Network)
por: Sammartano, Vincenzo, et al.
Publicado: (2022)

P22 THE PROGNOSTIC ROLE OF 1Q ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
por: Attucci, I., et al.
Publicado: (2023)

Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro‐prospective observational study
por: Del Giudice, Maria Livia, et al.
Publicado: (2022)

Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
por: Del Giudice, Maria Livia, et al.
Publicado: (2021)

P17 CLONAL PLASMA-CELLS IN STEM CELL APHERESIS AS A PREDICTOR OF PROGRESSION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELEGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
por: Pilerci, S., et al.
Publicado: (2023)

Anti-BCMA novel therapies for multiple myeloma
por: Sammartano, Vincenzo, et al.
Publicado: (2023)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications
por: Cencini, Emanuele, et al.
Publicado: (2023)

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Single Agent Lenalidomide Activity in Multiple Myeloma Relapse Evidenced Uniquely by CT/PET
por: Gozzetti, Alessandro, et al.
Publicado: (2012)

Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI
por: Santoni, Adele, et al.
Publicado: (2022)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Steps towards a Multiple Myeloma Cure?
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
por: Mele, Giuseppe, et al.
Publicado: (2018)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
por: Sonneveld, Pieter, et al.
Publicado: (2022)

Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma
por: GOZZETTI, ALESSANDRO, et al.
Publicado: (2023)

Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study
por: Astarita, Anna, et al.
Publicado: (2023)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
Publicado: (2023)

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
por: Leleu, Xavier, et al.
Publicado: (2022)

Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis
por: Onda, Yoshiyuki, et al.
Publicado: (2022)

Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
por: Biran, Noa, et al.
Publicado: (2019)

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan
por: Suzuki, Kenshi, et al.
Publicado: (2017)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network
por: Conticello, Concetta, et al.
Publicado: (2019)

“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
por: Pacelli, Paola, et al.
Publicado: (2022)

Case of Stroke from Cerebral Vasculitis following Carfilzomib, Lenalidomide, and Dexamethasone Therapy in a Patient with Relapsing Multiple Myeloma
por: Osafehinti, Deborah, et al.
Publicado: (2019)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

PB1986: ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SWITCHING FROM DOUBLET TO TRIPLET
por: Cerchione, C., et al.
Publicado: (2022)

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2023)

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
por: Rosenthal, A, et al.
Publicado: (2016)

Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement
por: Español, Ignacio, et al.
Publicado: (2017)

Optimizing carfilzomib use in multiple myeloma treatment
por: Yoon, Sung-Soo
Publicado: (2019)

The role of carfilzomib in relapsed/refractory multiple myeloma
por: Yee, Andrew J.
Publicado: (2021)

Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation
por: Buda, Gabriele, et al.
Publicado: (2021)

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
por: Dimopoulos, Meletios A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9j9m03jubasl8jb20ahg004sud